Publications

Putting Patient Uniqueness at the heart of Innovation

March 6, 2019

Access to innovative therapies remains an issue. In certain diseases, the magnitude and variability of individuals’ placebo response (IPR) can confound detection of positive results in clinical trials. Despite the best efforts and investments by pharmaceutical industry stakeholders, patients are still waiting for optimal treatments.

Type: Technology Presentation

Authors: Dominique Demolle, PhD; Stephanie Alvarez

Date: March 1, 2019

Conference: Patient Partnering in Clinical Development Conference

View

Leveraging historical data for high-dimensional regression adjustment, a machine learning approach.

June 6, 2018

The amount of data collected from patients involved in clinical trials is continuously growing. All those patient’s characteristics are potential covariates that could be used to improve study analysis and power. At the same time, the development of computerized systems simplifies the access to huge amount of historical data.

Type: Scientific Presentation

Authors: Samuel Branders, PhD; Guillaume Bernard, PhD; Alvaro Pereira, PhD

Date: June 3, 2018

Conference: Promoting Statistical Insight Conference

View

Baseline Pain Measurements As Predictors Of The Placebo Response In Neuropathic Patients

August 7, 2017

In analgesia randomized clinical trials (RCTs), the magnitude of the placebo response has a negative influence when testing the statistically significant superiority of active compounds compared to placebo.

Type: Scientific Poster

Authors: Alvaro Pereira, PHD; Samuel Branders, PHD; Christian Dualé, MD PHD; Fréderic Clermont, PHD; Pierre Gramme, MS; Chantal Gossuin, PHARMD; Dominique Demolle, PHD

Date: April 1, 2017

Conference: SIPS Conference

View

Bayesian Modeling Of The Placebo Response In Neuropathic Pain

August 7, 2017

In analgesia randomized clinical trials (RCTs), the magnitude and the variability of the placebo response have a negative influence when testing the statistically significant superiority of active compounds compared to placebo.

Type: Scientific Poster

Authors: Samuel Branders, PhD; Alvaro Pereira, PhD; Frederic Clermont, PhD; Chantal Gossuin; Dominique Demolle, PhD

Date: June 1, 2017

Conference: Promoting Statistical Insight Conference

View

Multifactorial Aspect Of The Placebo Analgesia Response In Peripheral Neuropathic Patients

August 7, 2016

The placebo response exerts a confusing influence when testing the statistically significant superiority of active compounds compared to placebo in analgesia randomized clinical trials (RCTs). Furthermore, the magnitude of this effect has tended to increase over time with the year of trial completion, including in neuropathic pain trials.

Type: Scientific Poster

Authors: Alvaro Pereira, PHD; Samuel Branders, PHD; Christian Dualé, MD PHD; Fréderic Clermont, PHD; Pierre Gramme, MS; Chantal Gossuin, PHARMD; Dominique Demolle, PHD.

Date: September 2, 2016

Conference: International Association for the Study of Pain Conference

View

Characterization And Prediction Of Placebo Responders In Peripheral Neuropathic Patients In A 4-week Analgesic Clinical Trial

August 7, 2016

In analgesia randomized clinical trials (RCTs), the magnitude of the placebo response tends to increase with the year of trial completion, including in neuropathic pain trials.

Type: Scientific Poster

Authors: Alvaro Pereira, PHD; Christian Dualé, MD PHD; Frédéric Clermont, PHD, Pierre Gramme, MS; Samuel Branders, PHD; Chantal Gossuin, PHARMD; Dominique Demolle, PHD

Date: March 1, 2016

Conference: American Pain Society Conference

View